What do systematic reviews say?

Very early treatment vs expectant management

Very early treatment showed no clear difference in chronic lung disease compared with expectant management (low certainty).

• Early treatment versus expectant management of hemodynamically significant patent ductus arteriosus for preterm infants 2020 · Cochrane Headline outcomes only
  RR 0.83 [0.63, 1.08]
  7 studies · 384 participants
  Low

Very early treatment vs expectant management

Very early treatment showed no clear difference in severe Intraventricular hemorrhage (grades III and IV) compared with expectant management (moderate certainty).

• Early treatment versus expectant management of hemodynamically significant patent ductus arteriosus for preterm infants 2020 · Cochrane Headline outcomes only
  RR 0.64 [0.21, 1.93]
  4 studies · 240 participants
  Moderate

Very early treatment vs expectant management

Very early treatment showed no clear difference in necrotizing enterocolitis (NEC; stage 2 or greater) compared with expectant management (moderate certainty).

• Early treatment versus expectant management of hemodynamically significant patent ductus arteriosus for preterm infants 2020 · Cochrane Headline outcomes only
  RR 1.08 [0.53, 2.21]
  5 studies · 332 participants
  Moderate

Very early treatment vs expectant management

• Early treatment versus expectant management of hemodynamically significant patent ductus arteriosus for preterm infants 2020 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 240 participants
  Low

Very early treatment vs expectant management

Very early treatment showed no clear difference in neurodevelopmental outcomes (moderate/severe cognitive delay at 18… compared with expectant management (low certainty).

• Early treatment versus expectant management of hemodynamically significant patent ductus arteriosus for preterm infants 2020 · Cochrane Headline outcomes only
  RR 0.27 [0.03, 2.31]
  1 study · 79 participants
  Low

Very early treatment vs expectant management

Very early treatment showed no clear difference in neurodevelopmental outcomes (moderate/severe motor delay at 18 to 24… compared with expectant management (low certainty).

• Early treatment versus expectant management of hemodynamically significant patent ductus arteriosus for preterm infants 2020 · Cochrane Headline outcomes only
  RR 0.54 [0.05, 5.71]
  1 study · 79 participants
  Low

Very early treatment vs expectant management

Very early treatment showed no clear difference in neurodevelopmental outcomes (moderate/severe language delay at 18 to… compared with expectant management (low certainty).

• Early treatment versus expectant management of hemodynamically significant patent ductus arteriosus for preterm infants 2020 · Cochrane Headline outcomes only
  RR 0.54 [0.1, 2.78]
  1 study · 79 participants
  Low

Very early treatment vs expectant management

Very early treatment showed no clear difference in all‐cause mortality during hospital stay compared with expectant management (moderate certainty).

• Early treatment versus expectant management of hemodynamically significant patent ductus arteriosus for preterm infants 2020 · Cochrane Headline outcomes only
  RR 0.94 [0.58, 1.53]
  7 studies · 384 participants
  Moderate

Very early treatment vs expectant management

Very early treatment showed no clear difference in proportion of infants requiring surgical PDA ligation or… compared with expectant management (moderate certainty).

• Early treatment versus expectant management of hemodynamically significant patent ductus arteriosus for preterm infants 2020 · Cochrane Headline outcomes only
  RR 0.88 [0.36, 2.17]
  5 studies · 293 participants
  Moderate

Very early treatment vs expectant management

It is very uncertain whether very early treatment changes proportion of infants receiving any pharmacotherapy for a… compared with expectant management (very low certainty).

• Early treatment versus expectant management of hemodynamically significant patent ductus arteriosus for preterm infants 2020 · Cochrane Headline outcomes only
  RR 1.64 [1.31, 2.05]
  4 studies · 156 participants
  Very low